Inventor · disambiguated record
Andrew Judd
Also filed as: JUDD ANDREW · JUDD ANDREW S
24 granted patents·58 pending applications·95 citations·filing 2003–2025
94Inventor score
Top patents by PatentIndex Score
82 records- 0193US8883784B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2013·Granted Nov 11, 2014·11 cites·14 claims
- 0292US8940737B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2012·Granted Jan 27, 2015·7 cites·10 claims
- 0392US7119205B2Thienopyridones as AMPK activators for the treatment of diabetes and obesityABBOTT LAB·Filed 2004·Granted Oct 10, 2006·47 cites·14 claims
- 0489US11964990B21,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitorsABBVIE INC·Filed 2023·Granted Apr 23, 2024·1 cites·2 claims
- 0589US10676485B2Macrocyclic MCL-1 inhibitors and methods of useABBVIE INC·Filed 2018·Granted Jun 9, 2020·2 cites·2 claims
- 0688US8889675B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2012·Granted Nov 18, 2014·3 cites·9 claims
- 0787US2024285611A1Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2023·Application pending·0 cites
- 0886US9266877B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2014·Granted Feb 23, 2016·2 cites·2 claims
- 0986US9227963B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2014·Granted Jan 5, 2016·2 cites·2 claims
- 1086US2025313572A1Macrocyclic mcl-1 inhibitors and methods of useABBVIE INC·Filed 2024·Application pending·0 cites
- 1184US10640563B2Anti-B7-H3 antibodies and antibody drug conjugatesABBVIE INC·Filed 2017·Granted May 5, 2020·3 cites·3 claims
- 1284US2025177374A1BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the SameABBVIE INC·Filed 2024·Application pending·0 cites
- 1382US2024228509A1Macrocyclic mcl-1 inhibitors and methods of useABBVIE INC·Filed 2023·Application pending·0 cites
- 1481US2025092062A1Macrocyclic mcl-1 inhibitors and methods of useABBVIE INC·Filed 2024·Application pending·0 cites
- 1581US2025213685A1Anti-egfr antibody drug conjugatesABBVIE INC·Filed 2024·Application pending·0 cites
- 1681US2025263491A1Anti-egfr antibody drug conjugatesABBVIE INC·Filed 2024·Application pending·0 cites
- 1779US9051327B2Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinasesABBVIE INC·Filed 2014·Granted Jun 9, 2015·2 cites·10 claims
- 1878US2023399340A1Macrocyclic mcl-1 inhibitors and methods of useABBVIE INC·Filed 2022·Application pending·0 cites
- 1977US12296000B2SLAM polynucleotides and polypeptides and uses thereofENG ANTIGENS INC·Filed 2023·Granted May 13, 2025·0 cites·16 claims
- 2077US9877958B2Apoptosis-induced agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2016·Granted Jan 30, 2018·1 cites·16 claims
- 2177US9844547B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2015·Granted Dec 19, 2017·1 cites·10 claims
- 2277US2024058450A1BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the SameABBVIE INC·Filed 2022·Application pending·0 cites
- 2377US2022259226A1Macrocyclic mcl-1 inhibitors and methods of useABBVIE INC·Filed 2022·Application pending·0 cites
- 2476US2025066388A11,3,4,7-tetrahydro-2h-pyrrolo[3',2':5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitorsABBVIE INC·Filed 2024·Application pending·0 cites
- 2575US8242139B2Inhibitors of diacylglycerol O-acyltransferase type 1 enzymeJUDD ANDREW S·Filed 2008·Granted Aug 14, 2012·3 cites·14 claims
- 2675US2023183261A1Macrocyclic MCL-1 Inhibitors and Methods of UseABBVIE INC·Filed 2022·Application pending·0 cites
- 2774US11786519B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2020·Granted Oct 17, 2023·0 cites·5 claims
- 2874US8796289B2Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinasesZHU GUI-DONG·Filed 2012·Granted Aug 5, 2014·2 cites·10 claims
- 2974US2024199745A1Anti-egfr antibody drug conjugatesABBVIE INC·Filed 2023·Application pending·0 cites
- 3074US2021403467A1Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2021·Application pending·0 cites
- 3174US2021346369A1Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2020·Application pending·0 cites
- 3273US7071182B2Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptorABBOTT LAB·Filed 2004·Granted Jul 4, 2006·6 cites·19 claims
- 3373US2020345717A1Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2019·Application pending·0 cites
- 3473US2020253954A1Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2019·Application pending·0 cites
- 3573US2020246460A1BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the SameABBVIE INC·Filed 2019·Application pending·0 cites
- 3673US2018354952A1Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2018·Application pending·0 cites
- 3773US2020331907A1Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2019·Application pending·0 cites
- 3872US2023114718A1Anti-egfr antibody drug conjugatesABBVIE INC·Filed 2022·Application pending·0 cites
- 3970US7834012B2Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)ABBOTT LAB·Filed 2006·Granted Nov 16, 2010·1 cites·10 claims
- 4070US2023077680A1Anti-egfr antibody drug conjugatesABBVIE INC·Filed 2021·Application pending·0 cites
- 4170US2018140595A1Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2017·Application pending·0 cites
- 4270US2021292339A1Macrocyclic mcl-1 inhibitors and methods of useABBVIE INC·Filed 2020·Application pending·0 cites
- 4370US2018221363A1Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2017·Application pending·0 cites
- 4468US2014275082A1Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2014·Application pending·0 cites
- 4568US2020325153A1Macrocyclic MCL-1 Inhibitors and Methods of UseABBVIE INC·Filed 2020·Application pending·0 cites
- 4666US11872275B2SLAM polynucleotides and polypeptides and uses thereofENG ANTIGENS INC·Filed 2021·Granted Jan 16, 2024·0 cites·15 claims
- 4766US10081628B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2016·Granted Sep 25, 2018·0 cites·1 claims
- 4865US2020255451A1Macrocyclic mcl-1 inhibitors and methods of useABBVIE INC·Filed 2018·Application pending·0 cites
- 4965US2019055264A1Macrocyclic MCL-1 inhibitors and methods of useABBVIE INC·Filed 2018·Application pending·0 cites
- 5065US2020239494A1Macrocyclic mcl-1 inhibitors and methods of useABBVIE INC·Filed 2018·Application pending·0 cites
Showing the top 50 of 82 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →